Abstract: Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.

Abstract: Provided herein are treatments for cancer by inhibition of USP7 activity, for example inhibition of USP7 activity in fibroblasts, inhibition of extra-cellular matrix remodelling in the tumour microenvironment, inhibition of VEGF, inhibition of angiogenesis or metastasis, modulation of the immune system, or a combination thereof.

Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those a compounds for use in methods of treating muscular atrophy.

Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.

Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

Abstract: Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.

Abstract: The present invention relates to pyrazolopyrimidinone derivatives, such as those of Formula (I), that are useful as inhibitors of the activity of Wee-1 kinase.

Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.

Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.

Abstract: The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

Abstract: The present invention relates to compounds of formula (I) that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

Abstract: The present invention relates to compounds of formula (I) that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Abstract: A process for extracting from aqueous solution the alkali metal or ammonium salt of a phenol, naphthol, anthrol or phenanthrol or the corresponding thiol, which comprises contacting an aqueous alkaline or neutral solution of the alkali metal or ammonium salt, in which is dissolved an alkali metal or ammonium fluoride, chloride, bromide, hydroxide, nitrate, nitrite, sulphate, sulphite, sulphide, thiosulphate, phosphate, hydrogen phosphate, carbonate, bicarbonate, cyanate, cyanide, thiocyanate, borate, chlorate, chlorite, hypochlorite, perchlorate, chromate, dichromate or permanganate, with a partially water-miscible organic solvent so as to transfer aqueous solution of the alkali metal or ammonium salt of the phenol, naphthol, anthrol or phenanthrol or corresponding thiol into the solvent while retaining separate aqueous and solvent phases, and thereafter separating the solvent phase containing the alkali metal or ammonium salt and water from the aqueous phase, the ratio of solvent to water in the separated so

Abstract: A process for extracting from aqueous solution the alkali metal or ammonium salt of a phenol, naphthol, anthrol or phenanthrol or the corresponding thiol, which comprises contacting an aqueous alkaline or neutral solution of the alkali metal or ammonium salt, in which is dissolved an alkali metal or ammonium fluoride, chloride, bromide, hydroxide, nitrate, nitrite, sulphate, sulphite, sulphide, thiosulphate, phosphate, hydrogen phosphate, carbonate, bicarbonate, cyanate, cyanide, thiocyanate, borate, chlorate, chlorite, hypochlorite, perchlorate, chromate, dichromate or permanganate, with a partially water-miscible organic solvent so as to transfer aqueous solution of the alkali metal or ammonium salt of the phenol, naphthol, anthrol or phenanthrol or corresponding thiol into the solvent whilst retaining separate aqueous and solvent phases, and thereafter separating the solvent phase containing the alkali metal or ammonium salt and water from the aqueous phase, the ratio of solvent to water in the separated s